Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non Operating Investment Income: 2015-2023

Historic Non Operating Investment Income for Ironwood Pharmaceuticals (IRWD) over the last 7 years, with Mar 2023 value amounting to $19,000.

  • Ironwood Pharmaceuticals' Non Operating Investment Income fell 97.40% to $19,000 in Q1 2023 from the same period last year, while for Mar 2023 it was -$529,000, marking a year-over-year increase of 81.36%. This contributed to the annual value of $19,000 for FY2023, which is 89.56% down from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Non Operating Investment Income of $19,000 as of Q1 2023, which was up 205.56% from -$18,000 recorded in Q4 2022.
  • Ironwood Pharmaceuticals' Non Operating Investment Income's 5-year high stood at $4.5 million during Q4 2019, with a 5-year trough of -$4.8 million in Q3 2019.
  • Moreover, its 3-year median value for Non Operating Investment Income was $19,000 (2023), whereas its average is -$108,556.
  • In the last 5 years, Ironwood Pharmaceuticals' Non Operating Investment Income surged by 199.70% in 2019 and then crashed by 710.95% in 2021.
  • Quarterly analysis of 5 years shows Ironwood Pharmaceuticals' Non Operating Investment Income stood at $4.5 million in 2019, then slumped by 90.70% to $420,000 in 2020, then crashed by 710.95% to -$2.6 million in 2021, then skyrocketed by 99.30% to -$18,000 in 2022, then plummeted by 97.40% to $19,000 in 2023.
  • Its Non Operating Investment Income was $19,000 in Q1 2023, compared to -$18,000 in Q4 2022 and $151,000 in Q3 2022.